BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2015-03-19 08:42 |
BioInvent reviderar klinisk strategi för BI-505; planerar fas IIa-studie i USA …
|
Swedish | 51.3 KB | ||
| 2015-03-19 08:42 |
BioInvent confirms clinical strategy for BI-505 and plans to conduct phase IIa …
|
English | 50.3 KB | ||
| 2015-03-17 08:30 |
BioInvent planerar att starta klinisk utveckling av TB-403 för behandling av pe…
|
Swedish | 47.5 KB | ||
| 2015-03-17 08:30 |
BioInvent announces plan to initiate clinical development of TB-403 in pediatri…
|
English | 46.4 KB | ||
| 2015-02-18 08:40 | Swedish | 184.3 KB | |||
| 2015-02-18 08:40 | English | 184.1 KB | |||
| 2015-01-22 08:30 |
BioInvent appoints head of clinical development
|
English | 26.8 KB | ||
| 2015-01-22 08:30 |
BioInvent utser chef för klinisk utveckling
|
Swedish | 44.4 KB | ||
| 2015-01-20 08:41 |
BioInvents antikropp BI-1206 avancerar till fas l/ll-studie med full finansieri…
|
Swedish | 68.5 KB | ||
| 2015-01-20 08:41 |
BioInvent’s BI-1206 antibody to enter collaborative Phase l/ll trial funded and…
|
English | 66.3 KB | ||
| 2014-10-23 08:40 | Swedish | 190.9 KB | |||
| 2014-10-23 08:40 | English | 190.2 KB | |||
| 2014-09-11 08:40 |
BioInvent receives another milestone payment from Bayer in connection with star…
|
English | 62.0 KB | ||
| 2014-09-11 08:40 |
BioInvent har erhållit ytterligare en milstolpsbetalning från Bayer i samband m…
|
Swedish | 28.7 KB | ||
| 2014-07-24 08:40 | Swedish | 487.9 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
